2023, Vol. 3, Issue 1, Part A
Formulation and evaluation of gastroretentive floating tablets of moxifloxacinAuthor(s):
The objective of the current study is to develop gastroretentive formulation for moxifloxacin using various drug release modifiers, moxifloxacin, novel synthetic fluoroquinolone, and antibacterial agent. Floating tablets of moxifloxacin. HCL were prepared using variable amounts of Eudragit RS with effervescent mixtures as per 32 factorial designs by direct compression technique. Amount of release modifiers required to obtain the prolonged release of drug was chosen as independent variables, X1 and X2, respectively, whereas time taken for 10%, 50%, 75%, and 90% of drug release were chosen as dependent variables. Nine formulations were developed and are checked for pharmacopeial tests. Results show that all the factorial batches were lie within the standard limits. Dissolution parameters of all formulations were subjected to kinetic fitting; various statistical parameters were determined. Polynomial equations were developed and verified for dependent variables. Formulation (F5) containing 50 mg of Eudragit RS is the best formulation showing similarity f2 = 71.733 and f1 = 4.272 with the marketed product (AVELOX). Formulation F5 follows Higuchi’s kinetics, Non-Fickian Diffusion, and first-order kinetics (n = 1.098). Pages: 54-58 | Views: 179 | Downloads: 59Download Full Article: Click Here
How to cite this article:
K Pallavi. Formulation and evaluation of gastroretentive floating tablets of moxifloxacin. Int J Pharm Sci Drug Anal 2023;3(1):54-58.